In Vitro Metabolism of DWP16001, a Novel Sodium-Glucose Cotransporter 2 Inhibitor, in Human and Animal Hepatocytes

In Vitro Metabolism of DWP16001, a Novel Sodium-Glucose Cotransporter 2 Inhibitor, in Human and Animal Hepatocytes

DWP16001 is currently in a phase 2 clinical trial as a novel anti-diabetes drug for the treatment of type 2 diabetes by selective inhibition of sodium-glucose cotransporter 2. This in vitro study was performed to compare the metabolism of DWP16001 in human, dog, monkey, mouse, and rat hepatocytes, a...

Full description

Bibliographic Details
Main Authors:	Ju-Hyun Kim, Dong Kyun Kim, Won-Gu Choi, Hye-Young Ji, Ji-Soo Choi, Im-Sook Song, Sangkyu Lee, Hye Suk Lee
Format:	Article
Language:	English
Published:	MDPI AG 2020-09-01
Series:	Pharmaceutics
Subjects:	DWP16001 SGLT2 inhibitor metabolism CYP UGT
Online Access:	https://www.mdpi.com/1999-4923/12/9/865

Similar Items

Evaluation of safety and anti-obesity effects of DWP16001 in naturally obese dogs
by: Beomseok Rhee, et al.
Published: (2022-06-01)

Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin
by: Min-Koo Choi, et al.
Published: (2020-03-01)

Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans
by: Min-Soo Kim, et al.
Published: (2023-03-01)

TRPV1 Antagonist DWP05195 Induces ER Stress-Dependent Apoptosis through the ROS-p38-CHOP Pathway in Human Ovarian Cancer Cells
by: Yi-Yue Wang, et al.
Published: (2020-06-01)

A first-in-human, double-blind, placebo-controlled, randomized, dose escalation study of DWP05195, a novel TRPV1 antagonist, in healthy volunteers
by: Lee J, et al.
Published: (2017-04-01)

Análise da relação entre normas de sistema de gestão (ISO 9001, ISO 14001, NBR 16001 e OHSAS 18001) e a sustentabilidade empresarial
by: Camila dos Santos Ferreira, et al.

Análise da relação entre normas de sistema de gestão (ISO 9001, ISO 14001, NBR 16001 e OHSAS 18001) e a sustentabilidade empresarial
by: Camila dos Santos Ferreira, et al.

Characterization of CYPs and UGTs Involved in Human Liver Microsomal Metabolism of Osthenol
by: Pil Joung Cho, et al.
Published: (2018-08-01)

In Vitro Metabolism of 25B-NBF, 2-(4-Bromo-2,5-Dimethoxyphenyl)-<i>N</i>-(2-Fluorobenzyl)ethanamine, in Human Hepatocytes Using Liquid Chromatography–Mass Spectrometry
by: Ju-Hyun Kim, et al.
Published: (2019-02-01)

Exploring the Metabolism of Loxoprofen in Liver Microsomes: The Role of Cytochrome P450 and UDP-Glucuronosyltransferase in Its Biotransformation
by: Riya Shrestha, et al.
Published: (2018-08-01)

Identification of α-Amyrin 28-Carboxylase and Glycosyltransferase From Ilex asprella and Production of Ursolic Acid 28-O-β-D-Glucopyranoside in Engineered Yeast
by: Xiaoyu Ji, et al.
Published: (2020-05-01)

Ontogeny of CYP3A and UGT activity in preterm piglets: a translational model for drug metabolism in preterm newborns
by: Laura Buyssens, et al.
Published: (2023-04-01)

Genome-wide Transcriptional Excavation of Dipsacus asperoides Unmasked both Cryptic Asperosaponin Biosynthetic Genes and SSR Markers
by: Jian-Ying eWang, et al.
Published: (2016-03-01)

Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes
by: Věra Čertíková Chábová, et al.
Published: (2022-03-01)

Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans
by: Yoo-Seong Jeong, et al.
Published: (2021-05-01)

In vitro metabolism, reaction phenotyping, enzyme kinetics, CYP inhibition and induction potential of ataluren
by: Ronald Kong, et al.
Published: (2020-04-01)

Crosstalk between Sodium–Glucose Cotransporter Inhibitors and Sodium–Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases
by: Al-Anood Al-Shamasi, et al.
Published: (2021-11-01)

Unfavorable effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the skeletal system of nondiabetic rats
by: Piotr Londzin, et al.
Published: (2022-11-01)

Sleeve Gastrectomy Surgery Improves Glucose Metabolism by Downregulating the Intestinal Expression of Sodium–Glucose Cotransporter-3
by: Yixing Ren, et al.
Published: (2022-01-01)

Model-Based Prediction of Acid Suppression and Proposal of a New Dosing Regimen of Fexuprazan in Humans
by: Min-Soo Kim, et al.
Published: (2022-06-01)

The Effect of Sodium–Glucose Cotransporter-2 Inhibitors on COVID-19 Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study Using the Common Data Model
by: Kyoung Ree Lim, et al.
Published: (2024-01-01)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
by: Xiaoya Sun, et al.
Published: (2022-12-01)

In Vitro Hepatic Assessment of Cineole and Its Derivatives in Common Brushtail Possums (<em>Trichosurus vulpecula</em>) and Rodents
by: Ravneel R. Chand, et al.
Published: (2021-12-01)

Sodium–glucose cotransporter‐2 inhibitors induced euglycemic diabetic ketoacidosis: Two case reports and a review of the literature
by: Zouheir Ibrahim Bitar, et al.
Published: (2022-02-01)

Sodium‐glucose cotransporter 2 inhibitors are associated with reduced risk of mortality and readmissions in heart failure
by: Patric Karlström, et al.
Published: (2024-02-01)

The Role of Sodium-Glucose Cotransporter-2 Inhibitors in the Treatment of Polycystic Ovary Syndrome: A Review
by: Rachel Porth, et al.
Published: (2024-02-01)

d-Allose is absorbed via sodium-dependent glucose cotransporter 1 (SGLT1) in the rat small intestine
by: Kunihiro Kishida, et al.
Published: (2021-09-01)

Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
by: Ahmadieh H, et al.
Published: (2017-05-01)

Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure
by: Ting-Wei Kao, et al.
Published: (2022-12-01)

Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review
by: Koichiro Matsumura, et al.
Published: (2019-11-01)

Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II–dependent kidney damage
by: Humberto Reyes-Pardo, et al.
Published: (2019-08-01)

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
by: Hang-Long Li, et al.
Published: (2021-05-01)

Metabolite Identification of a Novel Anti-Leishmanial Agent OJT007 in Rat Liver Microsomes Using LC-MS/MS
by: Maria Eugenia Rincon Nigro, et al.
Published: (2022-04-01)

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?
by: Anoushka Krishnan, et al.
Published: (2023-04-01)

The Effect of Sodium Glucose Cotransporter 2 Inhibitors From a Human Genetic Perspective
by: Xing-zi Liu, et al.
Published: (2021-03-01)

Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin
by: Sanon VP, et al.
Published: (2017-05-01)

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects
by: Atsuo Tahara, et al.
Published: (2016-03-01)

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
by: Derosa G, et al.
Published: (2018-09-01)

Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure
by: Alex Ali Sayour, et al.
Published: (2020-09-01)